ALGN vs. ZBH, SNN, MSA, ESTA, AVNS, INGN, EW, ARGX, CAH, and ICLR
Should you be buying Align Technology stock or one of its competitors? The main competitors of Align Technology include Zimmer Biomet (ZBH), Smith & Nephew (SNN), MSA Safety (MSA), Establishment Labs (ESTA), Avanos Medical (AVNS), Inogen (INGN), Edwards Lifesciences (EW), argenx (ARGX), Cardinal Health (CAH), and ICON Public (ICLR).
Align Technology (NASDAQ:ALGN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Zimmer Biomet received 124 more outperform votes than Align Technology when rated by MarketBeat users. However, 69.64% of users gave Align Technology an outperform vote while only 68.36% of users gave Zimmer Biomet an outperform vote.
Align Technology presently has a consensus target price of $341.36, indicating a potential upside of 8.10%. Zimmer Biomet has a consensus target price of $139.39, indicating a potential upside of 16.40%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Align Technology.
Zimmer Biomet has a net margin of 13.85% compared to Align Technology's net margin of 11.80%. Align Technology's return on equity of 14.22% beat Zimmer Biomet's return on equity.
88.4% of Align Technology shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.6% of Align Technology shares are owned by insiders. Comparatively, 1.0% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Align Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
In the previous week, Align Technology had 12 more articles in the media than Zimmer Biomet. MarketBeat recorded 32 mentions for Align Technology and 20 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.07 beat Align Technology's score of 0.56 indicating that Zimmer Biomet is being referred to more favorably in the news media.
Summary
Align Technology beats Zimmer Biomet on 10 of the 18 factors compared between the two stocks.
Get Align Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Align Technology Competitors List
Related Companies and Tools
